Financial Ratios MBX Biosciences, Inc.

Equities

MBX

US55287L1017

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-15 pm EDT			5-day change	1st Jan Change
32.96 ^USD	+0.46%		+4.11%	+4.50%

Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

685e835be45b04c20bfb.c6LsKIg7Z9jYDjNoL93mMutTQxH_2nbNL0NaiG24egA.Q9uiSf4PEaKib3ckH66HZrELDVCHsDmbVjQd-lrPK3c6kZlN10tTqrxBBw

Published financial data: MBX BIOSCIENCES, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2022	2023	2024	2025
Selling General & Admin Expenses, Total	3.86M	6.98M	10.98M	19.2M
R&D Expenses	21.3M	28.33M	57.22M	78.86M
Other Operating Expenses, Total	25.16M	35.31M	68.19M	98.06M
Operating Income	-25.16M	-35.31M	-68.19M	-98.06M
Interest Expense, Total	-374K	-	-	-
Interest And Investment Income	345K	1.7M	3.34M	7.47M
Net Interest Expenses	-29K	1.7M	3.34M	7.47M
Other Non Operating Income (Expenses)	-73K	-	-	-
EBT, Excl. Unusual Items	-25.26M	-33.61M	-64.85M	-90.58M
Gain (Loss) On Sale Of Investments	27K	1.04M	2.93M	3.61M
Other Unusual Items	-899K	-	-	-
EBT, Incl. Unusual Items	-26.14M	-32.56M	-61.92M	-86.97M
Earnings From Continuing Operations	-26.14M	-32.56M	-61.92M	-86.97M
Net Income to Company	-26.14M	-32.56M	-61.92M	-86.97M
Net Income - (IS)	-26.14M	-32.56M	-61.92M	-86.97M
Net Income to Common Incl Extra Items	-26.14M	-32.56M	-61.92M	-86.97M
Net Income to Common Excl. Extra Items	-26.14M	-32.56M	-61.92M	-86.97M
Per Share Items
Net EPS - Basic	-39.18	-31.96	-5.82	-2.38
Basic EPS - Continuing Operations	-39.18	-31.96	-5.82	-2.38
Basic Weighted Average Shares Outstanding	667K	1.02M	10.64M	36.51M
Net EPS - Diluted	-39.18	-31.96	-5.82	-2.38
Diluted EPS - Continuing Operations	-39.18	-31.96	-5.82	-2.38
Diluted Weighted Average Shares Outstanding	667K	1.02M	10.64M	36.51M
Normalized Basic EPS	-23.67	-20.62	-3.81	-1.55
Normalized Diluted EPS	-23.67	-20.62	-3.81	-1.55
Supplemental Items
EBITDA	-25.1M	-35.15M	-67.95M	-97.81M
EBITA	-25.16M	-35.31M	-68.19M	-98.06M
EBIT	-25.16M	-35.31M	-68.19M	-98.06M
EBITDAR	-25M	-34.95M	-67.75M	-97.51M
Normalized Net Income	-15.79M	-21M	-40.53M	-56.61M
Supplemental Operating Expense Items
General and Administrative Expenses	3.76M	6.78M	10.78M	18.9M
Research And Development Expense From Footnotes	21.4M	28.53M	57.42M	79.16M
Net Rental Expense, Total	100K	200K	200K	300K
Stock-Based Comp., R&D Exp. (Total)	93K	904K	2.54M	3.56M
Stock-Based Comp., G&A Exp. (Total)	213K	1.14M	2.68M	5.11M
Total Stock-Based Compensation	306K	2.04M	5.22M	8.68M

Fiscal Period: December	2022	2023	2024	2025
Assets
Cash And Equivalents	24.21M	30.52M	49.35M	75.29M
Short Term Investments	18.25M	50.15M	213M	298M
Total Cash And Short Term Investments	42.46M	80.68M	262M	374M
Other Receivables	142K	208K	682K	2.12M
Total Receivables	142K	208K	682K	2.12M
Prepaid Expenses	1.52M	2.45M	3.65M	4.85M
Other Current Assets, Total	84K	133K	803K	861K
Total Current Assets	44.21M	83.46M	267M	382M
Gross Property Plant And Equipment	898K	843K	1.62M	3.89M
Accumulated Depreciation	-56K	-178K	-422K	-670K
Net Property Plant And Equipment	842K	665K	1.2M	3.22M
Other Long-Term Assets, Total	42K	50K	50K	383K
Total Assets	45.1M	84.18M	269M	385M
Liabilities
Accounts Payable, Total	976K	1.39M	5.34M	2.98M
Accrued Expenses, Total	2.32M	2.38M	5.54M	12.35M
Current Portion of Leases	137K	153K	171K	172K
Total Current Liabilities	3.43M	3.93M	11.05M	15.5M
Long-Term Leases	324K	171K	-	424K
Other Non Current Liabilities	66K	194K	42K	2K
Total Liabilities	3.82M	4.29M	11.09M	15.92M
Preferred Stock Convertible	83.88M	152M	-	-
Total Preferred Equity	83.88M	152M	-	-
Common Stock, Total	1K	1K	5K	6K
Additional Paid In Capital	411K	3.05M	395M	593M
Retained Earnings	-43.02M	-75.58M	-138M	-224M
Comprehensive Income and Other	3K	60K	55K	286K
Total Common Equity	-42.6M	-72.47M	257M	369M
Total Equity	41.27M	79.89M	257M	369M
Total Liabilities And Equity	45.1M	84.18M	269M	385M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	667K	1.26M	33.42M	47.51M
ECS Total Common Shares Outstanding	667K	1.26M	33.42M	44.93M
Book Value / Share	-63.87	-57.65	7.7	8.22
Tangible Book Value	-42.6M	-72.47M	257M	369M
Tangible Book Value Per Share	-63.87	-57.65	7.7	8.22
Total Debt	461K	324K	171K	596K
Net Debt	-42M	-80.35M	-262M	-373M
Debt Equivalent Oper. Leases	800K	1.6M	1.6M	2.4M
Account Code - Inventory Valuation	-	3	3	3
Machinery, Total	227K	242K	1.11M	1.27M
Full Time Employees	-	27	43	63

Fiscal Period: December	2022	2023	2024	2025
Net Income	-26.14M	-32.56M	-61.92M	-86.97M
Depreciation & Amortization - CF	56K	157K	244K	348K
Depreciation & Amortization, Total	56K	157K	244K	348K
(Gain) Loss From Sale Of Asset	-	69K	-	-
(Gain) Loss on Sale of Investments - (CF)	-27K	-1.04M	-2.93M	-3.61M
Stock-Based Compensation (CF)	306K	2.04M	5.22M	8.68M
Other Operating Activities, Total	1.39M	95K	106K	33K
Change In Accounts Payable	671K	412K	3.93M	-2.46M
Change in Other Net Operating Assets	619K	-1.15M	670K	4.03M
Cash from Operations	-23.12M	-31.98M	-54.68M	-79.95M
Capital Expenditure	-441K	-129K	-874K	-1.93M
Investment in Marketable and Equity Securities, Total	-10.97M	-30.8M	-160M	-81.78M
Cash from Investing	-11.41M	-30.93M	-161M	-83.7M
Short Term Debt Issued, Total	10M	-	-	-
Total Debt Issued	10M	-	-	-
Issuance of Common Stock	30K	739K	175M	190M
Issuance of Preferred Stock	36.49M	68.51M	63.5M	-
Other Financing Activities, Total	-458K	-30K	-4.34M	-771K
Cash from Financing	46.06M	69.22M	234M	190M
Net Change in Cash	11.53M	6.31M	18.83M	25.94M
Supplemental Items
Levered Free Cash Flow	-	-20.56M	-33.27M	-52.44M
Unlevered Free Cash Flow	-	-20.56M	-33.27M	-52.44M
Change In Net Working Capital	-	560K	-4.76M	-1.75M
Net Debt Issued / Repaid	10M	-	-	-

Fiscal Period: December	2022	2023	2024	2025
Profitability
Return on Assets	-	-34.14	-24.17	-18.75
Return on Total Capital	-	-36.19	-25.23	-19.53
Return On Equity %	-	-53.75	-36.71	-27.76
Return on Common Equity	-	56.6	-66.95	-27.76
Short Term Liquidity
Current Ratio	12.89	21.26	24.19	24.62
Quick Ratio	12.42	20.6	23.78	24.25
Operating Cash Flow to Current Liabilities	-6.74	-8.15	-4.95	-5.16
Long Term Solvency
Total Debt/Equity	1.12	0.41	0.07	0.16
Total Debt / Total Capital	1.1	0.4	0.07	0.16
LT Debt/Equity	0.78	0.21	-	0.11
Long-Term Debt / Total Capital	0.78	0.21	-	0.11
Total Liabilities / Total Assets	8.47	5.1	4.13	4.13
EBIT / Interest Expense	-67.28	-	-	-
EBITDA / Interest Expense	-66.86	-	-	-
(EBITDA - Capex) / Interest Expense	-68.04	-	-	-
Total Debt / EBITDA	-0.02	-0.01	-0	-0.01
Net Debt / EBITDA	1.68	2.3	3.87	3.83
Total Debt / (EBITDA - Capex)	-0.02	-0.01	-0	-0.01
Net Debt / (EBITDA - Capex)	1.65	2.29	3.82	3.75
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	-	40.03	93.29	43.94
EBITA, 1 Yr. Growth %	-	40.34	93.12	43.79
EBIT, 1 Yr. Growth %	-	40.34	93.12	43.79
Earnings From Cont. Operations, 1 Yr. Growth %	-	24.6	90.16	40.45
Net Income, 1 Yr. Growth %	-	24.6	90.16	40.45
Normalized Net Income, 1 Yr. Growth %	-	33.03	92.97	39.68
Diluted EPS Before Extra, 1 Yr. Growth %	-	-18.42	-81.8	-59.05
Net Property, Plant and Equip., 1 Yr. Growth %	-	-21.02	80.3	168.72
Total Assets, 1 Yr. Growth %	-	86.67	219	43.42
Tangible Book Value, 1 Yr. Growth %	-	70.09	-455.25	43.42
Common Equity, 1 Yr. Growth %	-	70.09	-455.25	43.42
Cash From Operations, 1 Yr. Growth %	-	38.3	71	46.21
Capital Expenditures, 1 Yr. Growth %	-	-70.75	577.52	120.71
Levered Free Cash Flow, 1 Yr. Growth %	-	-	61.83	57.63
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	61.83	57.63
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	-	64.52	66.8
EBITA, 2 Yr. CAGR %	-	-	64.63	66.64
EBIT, 2 Yr. CAGR %	-	-	64.63	66.64
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	53.93	63.43
Net Income, 2 Yr. CAGR %	-	-	53.93	63.43
Normalized Net Income, 2 Yr. CAGR %	-	-	60.22	64.17
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-61.47	-72.7
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	19.33	120.12
Total Assets, 2 Yr. CAGR %	-	-	144.03	113.9
Tangible Book Value, 2 Yr. CAGR %	-	-	145.82	125.72
Common Equity, 2 Yr. CAGR %	-	-	145.82	125.72
Cash From Operations, 2 Yr. CAGR %	-	-	53.78	58.12
Capital Expenditures, 2 Yr. CAGR %	-	-	40.78	286.7
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-	59.72
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-	59.72
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	-	-	57.35
EBITA, 3 Yr. CAGR %	-	-	-	57.37
EBIT, 3 Yr. CAGR %	-	-	-	57.37
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	-	49.3
Net Income, 3 Yr. CAGR %	-	-	-	49.3
Normalized Net Income, 3 Yr. CAGR %	-	-	-	53.06
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	-60.68
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-	56.41
Total Assets, 3 Yr. CAGR %	-	-	-	104.41
Tangible Book Value, 3 Yr. CAGR %	-	-	-	105.4
Common Equity, 3 Yr. CAGR %	-	-	-	105.4
Cash From Operations, 3 Yr. CAGR %	-	-	-	51.22
Capital Expenditures, 3 Yr. CAGR %	-	-	-	63.54